ヒドロゲルを利用するメソトレキセート子宮内徐放化剤の試作と動物実験

概要

論文の詳細を見る
Two types of devices for sustained release of methotrexate in the uterus were prepared for the purpose of prevention of choriocarcinoma. One is a hydrogel piece of cross-linked copolymer of N-vinylpyrrolidone in which methotrexate is precipitated. The other is a hydrogel capsule made of the cross-linked blend of polyurethane and poly (N-vinylpyrrolidone) that is packed with methotrexate. In the experiment in vitro, the rate of the drug elution from the former device decreased as the elution proceeded. On the other hand, the elution rate was constant in the latter case in which the drug was released through the hydrogel membrane. In the animal experiments, the devices were inseredt into the uteri of rabbits. The elution rate in vivo was shown to be close to that in vitro in either case of the two types of devices. The numbers of white blood cells were found to be within a normal range in all the rabbits that had been dosed with 17-20mg of methotrexate in the uterus for 14 days. No abnormal symptom was recognized in macroscopic and histopathological examinations on the endometria of these rabbits.
日本膜学会の論文